Quantcast
Last updated on April 21, 2014 at 0:00 EDT

Latest ZIOPHARM Oncology Inc. Stories

2013-04-23 08:34:18

LONDON, April 23, 2013 /PRNewswire/ -- Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research and development will be crucial to boost product pipeline, major pharma companies may also benefit by collaborating with emerging biotechnology companies that have developed or are developing potential blockbuster drugs. Biotechnology stocks ended mostly lower on Monday even as...

2013-03-18 08:30:03

NEW YORK, March 18, 2013 /PRNewswire/ -- Today, Wall Street Source announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc....

2010-04-21 06:30:00

NEW YORK, April 21 /PRNewswire/ -- The Kristen Ann Carr Fund has awarded a grant to Jonathan Lewis, MD, PhD, Chief Executive Officer and Chief Medical Officer of ZIOPHARM Oncology, Inc., which will fund translational work at the Memorial Sloan-Kettering Cancer Center and the Albert Einstein College of Medicine in New York City, for the development of a novel treatment for pediatric sarcoma. The competitive grant was established to honor the 70th birthday of Murray F. Brennan, MD, Chairman...

2008-11-05 09:00:34

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 4:30 pm ET at the New York Palace Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at...

2008-11-03 09:00:39

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Company will host an analyst and institutional investor meeting on Thursday, November 20, 2008 from 7:30 A.M. to 10:00 A.M. Eastern Time in New York City. The event will be moderated by Jonathan Lewis, MD, PhD, Chief Executive Officer of ZIOPHARM and will include an in-depth discussion of the Company's product pipeline and clinical development strategy. The presentation will feature other members of the ZIOPHARM management...

2008-10-31 09:00:28

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today its financial results for the three and nine-month period ending September 30, 2008. The Company reported a lower net loss for the third quarter of 2008 of $5.5 million, or $(0.26) per share, compared with a net loss for the third quarter of 2007 of $7.3 million, or $(0.35) per share. Total operating expenses for the quarter were $5.6 million, compared with $7.9 million for the same quarter in the prior year. The decrease was...

2008-10-27 09:00:41

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive and Medical Officer, will present at the Oppenheimer & Co. 19th Annual Healthcare Conference on Monday, November 3, 2008 at 3:20 pm ET at the Waldorf-Astoria Hotel in New York City. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at...

2008-10-23 09:00:10

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that it presented darinaparsin (ZIO-101) mechanism of action data as well as preliminary data from Phase I studies with oral administration at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland. Data from preclinical studies on the molecular mechanism of action of darinaparsin were presented demonstrating that darinaparsin is highly active in a series of cell lines including those...

2008-10-15 09:00:47

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that the European Medicines Agency's (EMEA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion regarding ZIOPHARM's application for orphan medicinal product designation for palifosfamide in the treatment of soft tissue sarcoma (STS). In the European Union (EU), products targeted to treat life-threatening or very serious conditions that affect fewer than five in 10,000 people are eligible for orphan...

2008-09-30 09:01:00

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Maxim Group Growth Investor Conference on Tuesday, October 7, 2008 at 3:30 pm ET in the Morosco room at the Grand Hyatt Hotel in New York, NY. Dr. Lewis will provide an overview of the Company and its clinical development programs. The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast...